Prevención de miopatías por estatinas, una revisión bibliográfica

Las estatinas son fundamentales en el tratamiento de la dislipidemia y la prevención de enfermedades cardiovasculares, pero su uso puede verse limitado por la intolerancia o toxicidad. Entre estas complicaciones, las miopatías por estatinas varían en gravedad, desde mialgias leves hasta rabdomiólisi...

Full description

Autores:: Samper Garzón, Angy Carolina

Tipo de recurso:: https://purl.org/coar/resource_type/c_7a1f

Fecha de publicación:: 2024

Institución:: Universidad El Bosque

Repositorio:: Repositorio U. El Bosque

Idioma:: spa

id	UNBOSQUE2_890886f8668d2e5a782198b2fc30528f
oai_identifier_str	oai:repositorio.unbosque.edu.co:20.500.12495/12123
network_acronym_str	UNBOSQUE2
network_name_str	Repositorio U. El Bosque
repository_id_str
dc.title.none.fl_str_mv	Prevención de miopatías por estatinas, una revisión bibliográfica
dc.title.translated.none.fl_str_mv	Prevention of myopathies by statins, a literature review
title	Prevención de miopatías por estatinas, una revisión bibliográfica
spellingShingle	Prevención de miopatías por estatinas, una revisión bibliográfica Estatinas Miopatías Dislípidemia Intolerancia Rabdomiólisis Prevención 615.19 Statins Myopathies Dyslipidemia Intolerance Rhabdomyolysis Prevention
title_short	Prevención de miopatías por estatinas, una revisión bibliográfica
title_full	Prevención de miopatías por estatinas, una revisión bibliográfica
title_fullStr	Prevención de miopatías por estatinas, una revisión bibliográfica
title_full_unstemmed	Prevención de miopatías por estatinas, una revisión bibliográfica
title_sort	Prevención de miopatías por estatinas, una revisión bibliográfica
dc.creator.fl_str_mv	Samper Garzón, Angy Carolina
dc.contributor.advisor.none.fl_str_mv	Castillo Suarez, David German Vaca Alvarado, Leidy Johana
dc.contributor.author.none.fl_str_mv	Samper Garzón, Angy Carolina
dc.subject.none.fl_str_mv	Estatinas Miopatías Dislípidemia Intolerancia Rabdomiólisis Prevención
topic	Estatinas Miopatías Dislípidemia Intolerancia Rabdomiólisis Prevención 615.19 Statins Myopathies Dyslipidemia Intolerance Rhabdomyolysis Prevention
dc.subject.ddc.none.fl_str_mv	615.19
dc.subject.keywords.none.fl_str_mv	Statins Myopathies Dyslipidemia Intolerance Rhabdomyolysis Prevention
description	Las estatinas son fundamentales en el tratamiento de la dislipidemia y la prevención de enfermedades cardiovasculares, pero su uso puede verse limitado por la intolerancia o toxicidad. Entre estas complicaciones, las miopatías por estatinas varían en gravedad, desde mialgias leves hasta rabdomiólisis potencialmente fatal. Esta revisión bibliográfica realizó una exhaustiva búsqueda utilizando términos clave y bases de datos relevantes, siguiendo la metodología PRISMA. Se encontró que la prevalencia de miopatías por estatinas es baja, alrededor del 1%, pero la información disponible sobre este tema es limitada. La metodología de búsqueda incluyó la normalización de términos y la selección de artículos en español e inglés, con un límite temporal de 10 años. A pesar de la escasez de datos, se destaca la importancia de explorar alternativas para prevenir y tratar estas complicaciones, dada su significativa implicación en la seguridad y tolerabilidad del tratamiento con estatinas.
publishDate	2024
dc.date.accessioned.none.fl_str_mv	2024-05-15T19:19:18Z
dc.date.available.none.fl_str_mv	2024-05-15T19:19:18Z
dc.date.issued.none.fl_str_mv	2024-04
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv	Tesis/Trabajo de grado - Monografía - Pregrado
dc.type.coar.none.fl_str_mv	https://purl.org/coar/resource_type/c_7a1f
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.type.coarversion.none.fl_str_mv	https://purl.org/coar/version/c_ab4af688f83e57aa
format	https://purl.org/coar/resource_type/c_7a1f
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12495/12123
dc.identifier.instname.spa.fl_str_mv	Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv	repourl:https://repositorio.unbosque.edu.co
url	https://hdl.handle.net/20.500.12495/12123
identifier_str_mv	Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co
dc.language.iso.fl_str_mv	spa
language	spa
dc.relation.references.none.fl_str_mv	World Health Organization, "Cardiovascular diseases (CVDs)," [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) F. D. Arias Rodríguez et al., "Diagnóstico y tratamiento de enfermedad vascular periférica. Revisión bibliográfica," Angiología, vol. 74, no. 6, pp. 292-304, ene. 23, 2023, doi: 10.20960/angiologia.00421. N. J. Stone et al., "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines," Journal of the American College of Cardiology, vol. 63, no. 25 Part B, pp. 2889-2934, 2014, doi: 10.1016/j.jacc.2013.11.002. J. J. Kastelein y F. Akdim, "Statins: from plasma lowering to pleiotropy. Lessons from the heart," European Journal of Preventive Cardiology, vol. 23, no. 4, pp. 377-379, 2016, doi: 10.1177/2047487316641045. A. L. Zaleski, B. A. Taylor, y P. D. Thompson, "Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but…," Advances in Nutrition, vol. 9, no. 4, pp. 519S-523S, 2018, ISSN 2161-8313, doi: 10.1093/advances/nmy010. V. Mehta, R. Puri, P. B. Duell, et al., "Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid," The Journal of the Association of Physicians of India, vol. 70, no. 9, pp. 11-12, Sep. 2022, doi: 10.5005/japi-11001-0099. R. Cortés et al., "Miopatías metabólicas," Revista Médica Clínica Las Condes, vol. 29, no. 6, pp. 622-635, 2018, doi: 10.1016/j.rmclc.2018.09.004. A.R. Barry, J.E. Beach, and G.J. Pearson, "Prevention and management of statin adverse effects: A practical approach for pharmacists," Can. Pharm. J., vol. 151, pp. 92-102, 2018. [Online]. Available: doi: 10.1177/1715163518768534 R. Ariza Andraca, J. Halabe Cherem, and A. Lifshitz Guinzberg, "Intolerancia y miopatía por estatinas," Scielo, 2022. [Online]. Available: https://doi.org/10.35366/95407. P. Vinci, E. Panizon, L. M. Tosoni, C. Cerrato, F. Pellicori, F. Mearelli, C. Biasinutto, N. Fiotti, F. G. Di Girolamo, and G. Biolo, "Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy," Scopus, 2021. DOI: 10.3390/ijms222111687. J. Millán, J. Pedro-Botet, E. Climent, J. Millán, and J. Rius, "Miopatía asociada al uso de estatinas en la práctica clínica. Resultados del estudio DAMA," Elsevier, 2017. DOI: 10.1016/j.arteri.2016.07.003. J. M. Mostaza and C. Lahoz, "Main barriers in the management of dyslipidaemias: Intolerants," Elsevier, 2020. DOI: 10.1016/j.arteri.2020.12.003. Oltion Mesi, MD, Charlie Lin, MD, Haitham Ahmed, MD, MPH and Leslie S. Cho, MD “ Statin intolerance and new lipid-lowering treatments” Cleveland Clinic Journal of Medicine July 2021, 88 (7) 381-387; DOI: https://doi.org/10.3949/ccjm.88a.20165 G. Gheorghe, P. P. Toth, S. Bungau, T. Behl, M. Ilie, A. P. Stoian, O. G. Bratu, N. Bacalbasa, M. Rus, and C. C. Diaconu, "Cardiovascular Risk and Statin Therapy Considerations in Women," Diagnostics, vol. 10, no. 7, 2020, doi: 10.3390/diagnostics10070483. P. D. Thompson, G. Panza, A. Zaleski, and B. Taylor, "Statin-Associated Side Effects," J. Am. Coll. Cardiol., vol. 67, no. 20, May 24, 2016, pp. 2395-2410, doi: 10.1016/j.jacc.2016.02.071. C. A. German and J. K. Liao, "Understanding the molecular mechanisms of statin pleiotropic effects," Arch Toxicol, vol. 97, no. 6, pp. 1529-1545, Jun. 2023, doi: 10.1007/s00204-023-03492-6. Newman, C.B., Preiss, D., Tobert, J.A., Jacobson, T.A., Page, R.L., Goldstein, L.B., Chin, C., Tannock, L.R., Miller, M., Raghuveer, G., Duell, P.B., Brinton, E.A., Pollak, A., Braun, L.T., Welty, F.K., (2019). "Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association." Arteriosclerosis, Thrombosis, and Vascular Biology 39. https://doi.org/10.1161/atv.0000000000000073. Bair, T.L., May, H.T., Knowlton, K.U., Anderson, J.L., Lappe, D.L., Muhlestein, J.B. (2020). "Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study." J Cardiovasc Pharmacol, 75(5), 426-431. doi: 10.1097/FJC.0000000000000808. Margherita Bigossi, Cyrielle Maroteau, Adem Y Dawed, Alasdair Taylor, Sundararajan Srinivasan, Alaa’ Lufti Melhem, Ewan R Pearson, Roberto Pola, Colin N A Palmer, Moneeza K Siddiqui, A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 536–545, https://doi.org/10.1093/ehjcvp/pvad040 Bosco, G.; Di Giacomo Barbagallo, F.; Spampinato, S.; Lanzafame, L.; Di Pino, A.; Piro, S.; Purrello, F.; Scicali, R. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. J. Clin. Med. 2023, 12, 2444. https://doi.org/10.3390/jcm12062444 Niedrig, D.F., Pyra, M., Lussmann, R., Serra, A., Russmann, S. (2023). "Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients." Eur J Hosp Pharm. doi: 10.1136/ejhpharm-2023-003765. Epub ahead of print. PMID: 37451842 Warner M. Mampuya, David Frid, Michael Rocco, Julie Huang, Danielle M. Brennan, Stanley L. Hazen, Leslie Cho, "Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience," American Heart Journal, vol. 166, no. 3, pp. 597-603, 2013. DOI: 10.1016/j.ahj.2013.06.004. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. "Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management." Eur Heart J, vol. 36, no. 17, pp. 1012-1022, May 1, 2015. DOI: 10.1093/eurheartj/ehv043. Rosenson RS, Baker S, Banach M, Borrow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD. "Optimizing Cholesterol Treatment in Patients With Muscle Complaints." J Am Coll Cardiol, vol. 70, no. 10, pp. 1290-1301, 2017. DOI: 10.1016/j.jacc.2017.07.752. Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. "Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey." J Clin Lipidol, 2018. DOI: 10.1016/j.jacl.2017.09.006. Iatan I, Mancini GBJ, Yeoh E, Hegele RA. "Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management." Expert Rev Cardiovasc Ther 2023;21:423–435. DOI: 10.1080/14779072.2023.2215982. Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A, Gaita D, Latkovskis G, Mazidi M, Toth PP, Pella D, Alnouri F, Postadzhiyan A, Yeh H, Mancini GBJ, Von Haehling S, Banach M. "Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)." J Cachexia Sarcopenia Muscle 2022;13:1596–1622. DOI: 10.1002/jcsm.12960. Ward NC, Reid CM, Watts GF. "Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance." Front Cardiovasc Med. 2022. DOI: 10.3389/fcvm.2022.1060252. Ballantyne, C.M., Banach, M., Mancini, G.B.J., Lepor, N.E., Hanselman, J.C., Zhao, X., Leiter, L.A. "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study." Atherosclerosis. 2018. DOI: 10.1016/j.atherosclerosis.2018.06.002. Banach, M., Penson, P.E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., Vrablik, M., Escobar, C. "Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)." Progress in Cardiovascular Diseases, vol. 79, 2023, pp. 2-11. ISSN 0033-0620, DOI: 10.1016/j.pcad.2023.03.001. Kosmas, C.E., Pantou, D., Sourlas, A., Papakonstantinou, E.J., Echavarria Uceta, R., Guzman, E. "New and emerging lipid-modifying drugs to lower LDL cholesterol." Drugs Context, vol. 10, Nov. 2021, pp. 2021-8-3. DOI: 10.7573/dic.2021-8-3. A. Gupta y P. D. Thompson, "The relationship of vitamin D deficiency to statin myopathy," Atherosclerosis, vol. 215, no. 1, pp. 23–29, 2011, doi: 10.1016/j.atherosclerosis.2010.11.03. R. M. Papale y S. Schiaffino, "Manual de buenas prácticas de farmacovigilancia edición latinoamérica," 1a. ed. Ciudad Autónoma de Buenos Aires: Ediciones Farmacológicas, 2018. [Online]. Disponible en: [Archivo Digital: descarga y online]. ISBN 978-987-46704-2-7.
dc.rights.en.fl_str_mv	Attribution 4.0 International
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by/4.0/
dc.rights.local.spa.fl_str_mv	Acceso abierto
dc.rights.accessrights.none.fl_str_mv	info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.none.fl_str_mv	application/pdf
dc.publisher.program.spa.fl_str_mv	Química Farmacéutica
dc.publisher.grantor.spa.fl_str_mv	Universidad El Bosque
dc.publisher.faculty.spa.fl_str_mv	Facultad de Ciencias
institution	Universidad El Bosque
bitstream.url.fl_str_mv	https://repositorio.unbosque.edu.co/bitstreams/f0daedc6-1d67-4429-84ca-d1069b9102e1/download https://repositorio.unbosque.edu.co/bitstreams/cd39ad30-fa37-408b-81f4-f2c3c6729e98/download https://repositorio.unbosque.edu.co/bitstreams/4694889b-d6f6-4a32-a7a2-2ec4105dcc7e/download https://repositorio.unbosque.edu.co/bitstreams/57d74ba3-36cb-4737-bd54-29400889565c/download https://repositorio.unbosque.edu.co/bitstreams/c827fa0f-8939-4bdc-bdb5-be1e4f6f7940/download https://repositorio.unbosque.edu.co/bitstreams/0e81cb83-a3fc-4f02-89a4-49013d1b4fd9/download https://repositorio.unbosque.edu.co/bitstreams/883255d1-95f1-4243-831d-19b4c0a9c102/download
bitstream.checksum.fl_str_mv	59437e64e89e8cc34da2f092b8d17034 17cc15b951e7cc6b3728a574117320f9 bca2ded92077a7a4521e0d525e151190 c15deb0aead593bec48026a4b13669e7 adb7af3ef071a784ffe1b544b9a344ab 1b17832227e6254427aa49eddaad0124 0650efa4383628d8ef697680d42e5723
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv	bibliotecas@biteca.com
_version_	1814100674855567360
spelling	Castillo Suarez, David GermanVaca Alvarado, Leidy JohanaSamper Garzón, Angy Carolina2024-05-15T19:19:18Z2024-05-15T19:19:18Z2024-04https://hdl.handle.net/20.500.12495/12123Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coLas estatinas son fundamentales en el tratamiento de la dislipidemia y la prevención de enfermedades cardiovasculares, pero su uso puede verse limitado por la intolerancia o toxicidad. Entre estas complicaciones, las miopatías por estatinas varían en gravedad, desde mialgias leves hasta rabdomiólisis potencialmente fatal. Esta revisión bibliográfica realizó una exhaustiva búsqueda utilizando términos clave y bases de datos relevantes, siguiendo la metodología PRISMA. Se encontró que la prevalencia de miopatías por estatinas es baja, alrededor del 1%, pero la información disponible sobre este tema es limitada. La metodología de búsqueda incluyó la normalización de términos y la selección de artículos en español e inglés, con un límite temporal de 10 años. A pesar de la escasez de datos, se destaca la importancia de explorar alternativas para prevenir y tratar estas complicaciones, dada su significativa implicación en la seguridad y tolerabilidad del tratamiento con estatinas.PregradoQuímico FarmacéuticoStatins are essential in the treatment of dyslipidemia and the prevention of cardiovascular diseases, but their use may be limited by intolerance or toxicity. Among these complications, statin myopathies range in severity, from mild myalgias to potentially fatal rhabdomyolysis. This literature review carried out an exhaustive search using key terms and relevant databases, following the PRISMA methodology. The prevalence of statin myopathies was found to be low, around 1%, but the information available on this topic is limited. The search methodology included the standardization of terms and the selection of articles in Spanish and English, with a time limit of 10 years. Despite the scarcity of data, the importance of exploring alternatives to prevent and treat these complications is highlighted, given their significant implication in the safety and tolerability of statin treatment.application/pdfAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertoinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2EstatinasMiopatíasDislípidemiaIntoleranciaRabdomiólisisPrevención615.19StatinsMyopathiesDyslipidemiaIntoleranceRhabdomyolysisPreventionPrevención de miopatías por estatinas, una revisión bibliográficaPrevention of myopathies by statins, a literature reviewQuímica FarmacéuticaUniversidad El BosqueFacultad de CienciasTesis/Trabajo de grado - Monografía - Pregradohttps://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesishttps://purl.org/coar/version/c_ab4af688f83e57aaWorld Health Organization, "Cardiovascular diseases (CVDs)," [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)F. D. Arias Rodríguez et al., "Diagnóstico y tratamiento de enfermedad vascular periférica. Revisión bibliográfica," Angiología, vol. 74, no. 6, pp. 292-304, ene. 23, 2023, doi: 10.20960/angiologia.00421.N. J. Stone et al., "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines," Journal of the American College of Cardiology, vol. 63, no. 25 Part B, pp. 2889-2934, 2014, doi: 10.1016/j.jacc.2013.11.002.J. J. Kastelein y F. Akdim, "Statins: from plasma lowering to pleiotropy. Lessons from the heart," European Journal of Preventive Cardiology, vol. 23, no. 4, pp. 377-379, 2016, doi: 10.1177/2047487316641045.A. L. Zaleski, B. A. Taylor, y P. D. Thompson, "Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but…," Advances in Nutrition, vol. 9, no. 4, pp. 519S-523S, 2018, ISSN 2161-8313, doi: 10.1093/advances/nmy010.V. Mehta, R. Puri, P. B. Duell, et al., "Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid," The Journal of the Association of Physicians of India, vol. 70, no. 9, pp. 11-12, Sep. 2022, doi: 10.5005/japi-11001-0099.R. Cortés et al., "Miopatías metabólicas," Revista Médica Clínica Las Condes, vol. 29, no. 6, pp. 622-635, 2018, doi: 10.1016/j.rmclc.2018.09.004.A.R. Barry, J.E. Beach, and G.J. Pearson, "Prevention and management of statin adverse effects: A practical approach for pharmacists," Can. Pharm. J., vol. 151, pp. 92-102, 2018. [Online]. Available: doi: 10.1177/1715163518768534R. Ariza Andraca, J. Halabe Cherem, and A. Lifshitz Guinzberg, "Intolerancia y miopatía por estatinas," Scielo, 2022. [Online]. Available: https://doi.org/10.35366/95407.P. Vinci, E. Panizon, L. M. Tosoni, C. Cerrato, F. Pellicori, F. Mearelli, C. Biasinutto, N. Fiotti, F. G. Di Girolamo, and G. Biolo, "Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy," Scopus, 2021. DOI: 10.3390/ijms222111687.J. Millán, J. Pedro-Botet, E. Climent, J. Millán, and J. Rius, "Miopatía asociada al uso de estatinas en la práctica clínica. Resultados del estudio DAMA," Elsevier, 2017. DOI: 10.1016/j.arteri.2016.07.003.J. M. Mostaza and C. Lahoz, "Main barriers in the management of dyslipidaemias: Intolerants," Elsevier, 2020. DOI: 10.1016/j.arteri.2020.12.003.Oltion Mesi, MD, Charlie Lin, MD, Haitham Ahmed, MD, MPH and Leslie S. Cho, MD “ Statin intolerance and new lipid-lowering treatments” Cleveland Clinic Journal of Medicine July 2021, 88 (7) 381-387; DOI: https://doi.org/10.3949/ccjm.88a.20165G. Gheorghe, P. P. Toth, S. Bungau, T. Behl, M. Ilie, A. P. Stoian, O. G. Bratu, N. Bacalbasa, M. Rus, and C. C. Diaconu, "Cardiovascular Risk and Statin Therapy Considerations in Women," Diagnostics, vol. 10, no. 7, 2020, doi: 10.3390/diagnostics10070483.P. D. Thompson, G. Panza, A. Zaleski, and B. Taylor, "Statin-Associated Side Effects," J. Am. Coll. Cardiol., vol. 67, no. 20, May 24, 2016, pp. 2395-2410, doi: 10.1016/j.jacc.2016.02.071.C. A. German and J. K. Liao, "Understanding the molecular mechanisms of statin pleiotropic effects," Arch Toxicol, vol. 97, no. 6, pp. 1529-1545, Jun. 2023, doi: 10.1007/s00204-023-03492-6.Newman, C.B., Preiss, D., Tobert, J.A., Jacobson, T.A., Page, R.L., Goldstein, L.B., Chin, C., Tannock, L.R., Miller, M., Raghuveer, G., Duell, P.B., Brinton, E.A., Pollak, A., Braun, L.T., Welty, F.K., (2019). "Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association." Arteriosclerosis, Thrombosis, and Vascular Biology 39. https://doi.org/10.1161/atv.0000000000000073.Bair, T.L., May, H.T., Knowlton, K.U., Anderson, J.L., Lappe, D.L., Muhlestein, J.B. (2020). "Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study." J Cardiovasc Pharmacol, 75(5), 426-431. doi: 10.1097/FJC.0000000000000808.Margherita Bigossi, Cyrielle Maroteau, Adem Y Dawed, Alasdair Taylor, Sundararajan Srinivasan, Alaa’ Lufti Melhem, Ewan R Pearson, Roberto Pola, Colin N A Palmer, Moneeza K Siddiqui, A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 536–545, https://doi.org/10.1093/ehjcvp/pvad040Bosco, G.; Di Giacomo Barbagallo, F.; Spampinato, S.; Lanzafame, L.; Di Pino, A.; Piro, S.; Purrello, F.; Scicali, R. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. J. Clin. Med. 2023, 12, 2444. https://doi.org/10.3390/jcm12062444Niedrig, D.F., Pyra, M., Lussmann, R., Serra, A., Russmann, S. (2023). "Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients." Eur J Hosp Pharm. doi: 10.1136/ejhpharm-2023-003765. Epub ahead of print. PMID: 37451842Warner M. Mampuya, David Frid, Michael Rocco, Julie Huang, Danielle M. Brennan, Stanley L. Hazen, Leslie Cho, "Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience," American Heart Journal, vol. 166, no. 3, pp. 597-603, 2013. DOI: 10.1016/j.ahj.2013.06.004.Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. "Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management." Eur Heart J, vol. 36, no. 17, pp. 1012-1022, May 1, 2015. DOI: 10.1093/eurheartj/ehv043.Rosenson RS, Baker S, Banach M, Borrow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD. "Optimizing Cholesterol Treatment in Patients With Muscle Complaints." J Am Coll Cardiol, vol. 70, no. 10, pp. 1290-1301, 2017. DOI: 10.1016/j.jacc.2017.07.752.Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. "Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey." J Clin Lipidol, 2018. DOI: 10.1016/j.jacl.2017.09.006.Iatan I, Mancini GBJ, Yeoh E, Hegele RA. "Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management." Expert Rev Cardiovasc Ther 2023;21:423–435. DOI: 10.1080/14779072.2023.2215982.Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A, Gaita D, Latkovskis G, Mazidi M, Toth PP, Pella D, Alnouri F, Postadzhiyan A, Yeh H, Mancini GBJ, Von Haehling S, Banach M. "Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)." J Cachexia Sarcopenia Muscle 2022;13:1596–1622. DOI: 10.1002/jcsm.12960.Ward NC, Reid CM, Watts GF. "Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance." Front Cardiovasc Med. 2022. DOI: 10.3389/fcvm.2022.1060252.Ballantyne, C.M., Banach, M., Mancini, G.B.J., Lepor, N.E., Hanselman, J.C., Zhao, X., Leiter, L.A. "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study." Atherosclerosis. 2018. DOI: 10.1016/j.atherosclerosis.2018.06.002.Banach, M., Penson, P.E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., Vrablik, M., Escobar, C. "Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)." Progress in Cardiovascular Diseases, vol. 79, 2023, pp. 2-11. ISSN 0033-0620, DOI: 10.1016/j.pcad.2023.03.001.Kosmas, C.E., Pantou, D., Sourlas, A., Papakonstantinou, E.J., Echavarria Uceta, R., Guzman, E. "New and emerging lipid-modifying drugs to lower LDL cholesterol." Drugs Context, vol. 10, Nov. 2021, pp. 2021-8-3. DOI: 10.7573/dic.2021-8-3.A. Gupta y P. D. Thompson, "The relationship of vitamin D deficiency to statin myopathy," Atherosclerosis, vol. 215, no. 1, pp. 23–29, 2011, doi: 10.1016/j.atherosclerosis.2010.11.03.R. M. Papale y S. Schiaffino, "Manual de buenas prácticas de farmacovigilancia edición latinoamérica," 1a. ed. Ciudad Autónoma de Buenos Aires: Ediciones Farmacológicas, 2018. [Online]. Disponible en: [Archivo Digital: descarga y online]. ISBN 978-987-46704-2-7.spaORIGINALTrabajo de gradoTrabajo de gradoapplication/pdf2352495https://repositorio.unbosque.edu.co/bitstreams/f0daedc6-1d67-4429-84ca-d1069b9102e1/download59437e64e89e8cc34da2f092b8d17034MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-82000https://repositorio.unbosque.edu.co/bitstreams/cd39ad30-fa37-408b-81f4-f2c3c6729e98/download17cc15b951e7cc6b3728a574117320f9MD52Anexo 1 Acta de aprobacion.pdfapplication/pdf1351676https://repositorio.unbosque.edu.co/bitstreams/4694889b-d6f6-4a32-a7a2-2ec4105dcc7e/downloadbca2ded92077a7a4521e0d525e151190MD513Carta de autorizacion.pdfapplication/pdf110965https://repositorio.unbosque.edu.co/bitstreams/57d74ba3-36cb-4737-bd54-29400889565c/downloadc15deb0aead593bec48026a4b13669e7MD514CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81154https://repositorio.unbosque.edu.co/bitstreams/c827fa0f-8939-4bdc-bdb5-be1e4f6f7940/downloadadb7af3ef071a784ffe1b544b9a344abMD55TEXTTrabajo de grado.txtTrabajo de grado.txtExtracted texttext/plain53184https://repositorio.unbosque.edu.co/bitstreams/0e81cb83-a3fc-4f02-89a4-49013d1b4fd9/download1b17832227e6254427aa49eddaad0124MD59THUMBNAILTrabajo de grado.jpgTrabajo de grado.jpgGenerated Thumbnailimage/jpeg4774https://repositorio.unbosque.edu.co/bitstreams/883255d1-95f1-4243-831d-19b4c0a9c102/download0650efa4383628d8ef697680d42e5723MD51020.500.12495/12123oai:repositorio.unbosque.edu.co:20.500.12495/121232024-07-04 09:56:02.819http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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

Prevención de miopatías por estatinas, una revisión bibliográfica

Publicaciones similares